- IN-VITRO RESEARCH ONLY — NOT FOR HUMAN USE
Semaglutide
Price range: £60.00 through £150.00
- Ships Today if ordered
- Free international delivery within 1-3 business days on orders over $600, with a tracking number provided.
- Third party tested
Characteristics
How does Semaglutide work?
Research
Semaglutide is a research‑grade peptide designed to deliver precision, purity, and reliability for advanced scientific studies. Verified at 99% purity, it ensures reproducibility and consistency across laboratory applications. Each vial is carefully packaged to maintain stability and integrity during storage and handling. Rigorous third‑party testing provides researchers with confidence in their results, making Semaglutide a trusted choice for peptide‑based investigations. Strictly intended for research use only, this compound empowers scientists to accelerate discovery, validate experimental approaches, and explore innovative pathways in biotechnology, pharmacology, and metabolic research. Its dependability and quality make it an essential tool for cutting‑edge science.
Side Effects
Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is generally well tolerated but shares the common side effect profile of GLP‑1 receptor agonists. The most frequently reported issues are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain, particularly during dose escalation. Because it slows gastric emptying and reduces appetite, some individuals experience bloating or indigestion. Other reported effects include headache, dizziness, and fatigue. Injection site reactions such as redness or irritation are usually mild and temporary. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid C‑cell tumors, which is why Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Hypoglycemia can occur when combined with other glucose‑lowering medications, though it is uncommon when used alone. Overall, the side effect profile is consistent with its mechanism of action, and careful dose titration helps improve tolerability.
Summary
References
Semaglutide is a GLP‑1 receptor agonist developed by Novo Nordisk, marketed under the names Ozempic, Rybelsus, and Wegovy. It mimics the natural incretin hormone GLP‑1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. Its molecular modifications allow albumin binding, extending half‑life and enabling once‑weekly dosing for injectable forms, while an oral tablet version is also available. Clinical trials such as SUSTAIN (for type 2 diabetes) and STEP (for obesity) have demonstrated significant HbA1c reductions, substantial weight loss, and proven cardiovascular risk reduction in high‑risk patients. Regulatory approvals have been granted globally for type 2 diabetes and chronic weight management. Reported side effects are primarily gastrointestinal, with rare risks including pancreatitis, gallbladder disease, and thyroid C‑cell tumors.
Resource
Member-only Access
Why become a member?
- Full access to our research peptide catalog.
- Expert guidance for lab experiments.
- Free educational resources on peptides.
- Exclusive discounts on orders.
- Latest insights via blogs and podcasts.
Your Trusted Partner for High-Quality Research Peptides
Superior Quality Assurance
Peptide Chemists ensures every peptide meets strict quality and purity standards through rigorous formulation and premium material sourcing.
Independently Validated
All products are tested in-house and by third-party labs, guaranteeing verified purity, concentration, and reliability.
Rapid Delivery & Professional Support
Peptide Chemists provides secure, prompt shipping and expert technical support for accurate and reliable laboratory use.
Reviews
There are no reviews yet.